Oragenics Implements 1-for-30 Reverse Stock Split to Enhance Market Appeal
Biotechnology company Oragenics will execute a reverse stock split to improve its capital markets positioning and potentially attract long-term investors, consolidating 30 existing shares into one new share.
Oragenics Inc. will implement a 1-for-30 reverse stock split of its common shares, effective June 3, 2025, in a strategic move to boost its share price and market attractiveness. The biotechnology company, listed on the NYSE American under the ticker symbol 'OGEN', will consolidate every 30 outstanding shares into a single share.
CEO Janet Huffman emphasized that the stock split aligns with the company's broader strategy to enhance its capital markets profile. By reducing the total number of outstanding shares, Oragenics aims to potentially increase investor confidence and appeal to long-term investment strategies.
The reverse stock split will not alter the company's fundamental value but is designed to improve its financial presentation. Shares will continue trading under the 'OGEN' symbol, with a new CUSIP number reflecting the adjusted share structure.
Oragenics, a development-stage biotechnology firm, remains focused on advancing pharmaceutical treatments, particularly in neurology and infectious disease domains. The company is developing nasal delivery medications targeting conditions such as mild traumatic brain injury and Niemann Pick Disease Type C.
Investors should note that while the total value of their holdings remains unchanged, the number of shares will be proportionally reduced. This financial maneuver is a common strategy for companies seeking to manage their market perception and potentially attract more institutional investors.